M
MaxCyte Inc
NASDAQ:MXCT
MaxCyte Inc
NASDAQ:MXCT
Price:
0.7383
USD
0.78%
Market Closed
Market Cap:
$78.8m
Relative Value
The Relative Value of one MXCT stock under the Base Case scenario is 2.1448 USD. Compared to the current market price of 0.7383 USD, MaxCyte Inc is Undervalued by 66%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MXCT
Relative Value
Base Case
2.1448
USD
Undervaluation 66%
M
Multiples Across Competitors
MXCT Competitors Multiples
MaxCyte Inc Competitors
MaxCyte Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
M
|
MaxCyte Inc
NASDAQ:MXCT
|
78.1m USD | 2.4 | -1.8 | 0.6 | 0.5 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD | 375.4 | 4 444.8 | 1 409.2 | 3 011 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
191.7B USD | 4.3 | 28.7 | 20 | 26.9 | |
| US |
|
Danaher Corp
NYSE:DHR
|
148.4B USD | 6.1 | 41.2 | 22.8 | 34.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
79.2T KRW | 8.4 | 29 | 29.1 | 38.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
36.8B CHF | 5.7 | 39.3 | 28.8 | 28.8 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
291.5B CNY | 6.6 | 19.4 | 19.7 | 19.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.7B USD | 5 | 26.6 | 19.4 | 23 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.2B USD | 1.7 | 20.6 | 11.6 | 17.4 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.1B USD | 7 | 32.3 | 23.8 | 26.5 | |
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
164.6B HKD | 7.3 | 34.7 | 24.4 | 24.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
